L01EJ Janus-associated kinase (JAK) inhibitors L01EJ01 Ruxolitinib L01EJ02 Fedratinib L01EJ03 Pacritinib L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors L01EK01 Axitinib L01EK02 Cediranib L01EK03 Tivozanib L01EL Bruton's tyrosine kinase (BTK) inhibitors L01EL01 Ibrutinib L01EL02 Acalabrutinib L01EL03 Zanubrutinib L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors L01EM01 Idelalisib L01EM02 Copanlisib L01EM03 Alpelisib L01EM04 Duvelisib L01EM05 Parsaclisib L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors L01EN01 Erdafitinib L01EN02 Pemigatinib L01EN03 Infigratinib L01EN04 Futibatinib L01EX Other protein kinase inhibitors L01EX01 Sunitinib L01EX02 Sorafenib L01EX03 Pazopanib L01EX04 Vandetanib L01EX05 Regorafenib L01EX06 Masitinib L01EX07 Cabozantinib L01EX08 Lenvatinib L01EX09 Nintedanib L01EX10 Midostaurin L01EX11 Quizartinib L01EX12 Larotrectinib L01EX13 Gilteritinib L01EX14 Entrectinib L01EX15 Pexidartinib L01EX17 Capmatinib L01EX18 Avapritinib L01EX19 Ripretinib L01EX21 Tepotinib L01EX22 Selpercatinib L01EX23 Pralsetinib L01EX24 Surufatinib L01EX25 Umbralisib QL01EX90 Toceranib L01F Monoclonal antibodies and antibody drug conjugates L01FA CD20 (Clusters of Differentiation 20) inhibitors L01FA01 Rituximab L01FA02 Ofatumumab L01FA03 Obinutuzumab L01FB CD22 (Clusters of Differentiation 22) inhibitors L01FB01 Inotuzumab ozogamicin L01FB02 Moxetumomab pasudotox L01FC CD38 (Clusters of Differentiation 38) inhibitors L01FC01 Daratumumab L01FC02 Isatuximab L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors L01FD01 Trastuzumab L01FD02 Pertuzumab L01FD03 Trastuzumab emtansine L01FD04 Trastuzumab deruxtecan L01FD05 Trastuzumab duocarmazine L01FD06 Margetuximab L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors L01FE01 Cetuximab L01FE02 Panitumumab L01FE03 Necitumumab L01FF PD-1/PDL-1 (Programmed cell death protein 1/ death ligand 1) inhibitors L01FF01 Nivolumab L01FF02 Pembrolizumab L01FF03 Durvalumab L01FF04 Avelumab L01FF05 Atezolizumab L01FF06 Cemiplimab L01FF07 Dostarlimab L01FF08 Prolgolimab L01FF09 Tislelizumab L01FF10 Retifanlimab L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors L01FG01 Bevacizumab L01FG02 Ramucirumab L01FX Other monoclonal antibodies and antibody drug conjugates L01FX01 Edrecolomab L01FX02 Gemtuzumab ozogamicin L01FX03 Catumaxomab L01FX04 Ipilimumab L01FX05 Brentuximab vedotin L01FX06 Dinutuximab beta L01FX07 Blinatumomab L01FX08 Elotuzumab L01FX09 Mogamulizumab L01FX10 Olaratumab L01FX11 Bermekimab L01FX12 Tafasitamab L01FX13 Enfortumab vedotin L01FX14 Polatuzumab vedotin L01FX15 Belantamab mafodotin L01FX16 Oportuzumab monatox L01FX17 Sacituzumab govitecan L01FX18 Amivantamab L01FX19 Sabatolimab L01FX20 Tremelimumab L01FX21 Naxitamab L01FX22 Loncastuximab tesirine L01FX23 Tisotumab vedotin L01X Other antineoplastic agents L01XA Platinum compounds L01XA01 Cisplatin L01XA02 Carboplatin L01XA03 Oxaliplatin L01XA04 Satraplatin L01XA05 Polyplatillen L01XB Methylhydrazines L01XB01 Procarbazine L01XD Sensitizers used in photodynamic/radiation therapy L01XD01 Porfimer sodium L01XD03 Methyl aminolevulinate L01XD04 Aminolevulinic acid L01XD05 Temoporfin L01XD06 Efaproxiral L01XD07 Padeliporfin L01XF Retinoids for cancer treatment L01XF01 Tretinoin L01XF02 Alitretinoin L01XF03 Bexarotene L01XG Proteasome inhibitors L01XG01 Bortezomib L01XG02 Carfilzomib L01XG03 Ixazomib L01XH Histone deacetylase (HDAC) inhibitors L01XH01 Vorinostat L01XH02 Romidepsin L01XH03 Panobinostat L01XH04 Belinostat L01XH05 Entinostat L01XJ Hedgehog pathway inhibitors L01XJ01 Vismodegib L01XJ02 Sonidegib L01XJ03 Glasdegib L01XK Poly (ADP-ribose)